Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

Philip McGuire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright

Research output: Contribution to journalArticlepeer-review

414 Citations (Scopus)

Abstract

Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.
Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalThe American Journal of Psychiatry
Volume175
Issue number3
Early online date15 Dec 2017
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Treatment
  • Schizophrenia
  • Cannabidiol
  • Psychosis
  • Clinical Tria

Fingerprint

Dive into the research topics of 'Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial'. Together they form a unique fingerprint.

Cite this